GVK BIO a leading small-molecule contract research organization (CRO) has announced acquisition of US-based Aragen Bioscience Inc. a pre-clinical CRO specialising in high-value biologics services. The Hyderabad-based company Wednesday said it entered into an agreement to acquire the capital stock of Aragen Biosciences. It however has not disclosed financial details of its first overseas acquisition. This acquisition provides GVK with world-class expertise in large molecule research and development services and high-content biological services the company said in a statement. Combined with GVK BIO's established small molecule discovery and development capabilities this expansion uniquely position GVK BIO as a leading provider
